Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 3, Mars 2002
Page(s) 343 - 352
Section M/S Revues : Articles de Synthèse
DOI http://dx.doi.org/10.1051/medsci/2002183343
Publié en ligne 15 mars 2002
  1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 226 : 347–56.
  2. Thomas HC, Törok ME, Forton DM, et al. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 32 (suppl 1) : 152–9.
  3. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282 : 103–7.
  4. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6 : 1375–9.
  5. Hultgren C, Milich DR, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79 : 2381–91.
  6. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-a therapy. Ann Intern Med 1997; 127 : 875–81.
  7. Duchatelle V, Marcellin P, Giostra E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assement by a morphometric method. J Hepatol 1998; 29 : 20–8.
  8. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon : a preliminary report. N Engl J Med 1986; 315 : 1575–8.
  9. Marcellin P. Traitement de l’hépatite C par l’interféron. Conférence de Consensus - Textes des experts. Comment traiter l’hépatite C ? Gastroenterol Clin Biol 1997; 20 : S81–S88.
  10. Shiffman ML. Use of highdose interferon in the treatment of chronic hepatitis C. Sem Liver Dis. 1999; 19 (Suppl 1) : 25–33.
  11. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352 : 1426–32.
  12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339 : 1485–92.
  13. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956–61
  14. Boyer N, Marcellin P. L’interféron pegylé : nouveau progrès dans le traitement de l’hépatite chronique C. Gastroentérol Clin Biol 2000; 24 : 767–9.
  15. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343 : 1666–72.
  16. Lindsay KL, Trépo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34 : 395–403
  17. Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with IFN-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial. Lancet 2001; 358 : 958–65.
  18. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin : efficacy and safety results from a phase III, randomized, activelycontrolled, multicenter study. Gastroenteroly 2001; 120 : A55 (abstract).
  19. Chow WC, Boyer N, Pouteau M, et al. Retreatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998; 27 : 1144–8.
  20. Pol S, Couzigou P, Bourlière M, et al. A randomized trial of ribavirin and interferon-a vs, interferon-a alone in patients with chronic hepatitis C who were nonresponders to a previous treatment. J Hepatol 1999; 31 : 1–7.
  21. Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32 : 630–4.
  22. Wright M, main J, Thomas HC. Drug-resistant viral hepatitis. J Infect 2000; 41 : 1–4.
  23. Valla D, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis. A randomized controlled trial of IFN-2b versus non treatment. Hepatology 1999; 29 : 1870–5.
  24. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis : analysis of individual patient data of six controlled trials. Gastroenterology 1999; 117 : 408–13.
  25. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346 : 1051–5.
  26. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C : a retrospective followup study of 384 patients. Gastroenterology 1997; 112 : 463–72.
  27. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronichepatitis C in Japan. Ann Intern Med 1999; 131 : 174–81.
  28. Marcellin P. Hepatitis C : the clinical spectrum of the disease. J Hepatol 1999; 31 : (suppl 1) : 9–16.
  29. Marcellin P, Lévy S, Erlinger S. Treatment of patients with chronic HCV infection with normal serum ALT levels. Hepatology 1997; 26 (suppl 1) : 133S–136S.
  30. Poynard T. Quelles sont les indications du traitement dans l’hépatite aiguë C ? Gastroenterol Clin Biol 1997; 21 : S66–S69.
  31. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345 : 1452–7.
  32. Gervais A, Boyer N, Marcellin P. Co-infection VIH-VHC en l’an 2001. La lettre de l’infectiologue 2001; Tome XVI, N° 6 : 186–90.
  33. Causse X, Payen JL, Izopet J, Babany G, Saint Marc Girardin MF and the French Multicenter Study Group. Does HIV-infection influence the response of chronic hepatitis C to interferon treatment ? A French multicenter prospective study. J Hepatol 2000; 32: 1003–10.
  34. Landau A, Batisse D, Duong Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-a 2b and ribavirin for chronic hepatitis C in HIV infected patients. AIDS 2000; 14 : 839–44.
  35. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferonribavirin combination therapy in HCV-HIV coinfected subjects : an early report. Gut 2000; 47 : 608–9.
  36. Féray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C.Gastroenterology 1999; 117 : 619–25.
  37. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26 : 500–504.
  38. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France : relationship with epidemiology, pathogenicity and response to interferon therapy J Viral Hepatitis 1999; 6 : 435–43.
  39. Martinot-Peignoux M, Boyer N, Pouteau M, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29 : 214–23.
  40. Gervais A, Boyer B, Marcellin P. Tolerability of treatments for viral hepatitis. In Drug Safety. Ed. Adis international Ltd, Auckland, New Zealand, Vol. 24, N° 5, 2001 pp375–384.
  41. Asselah T, Martinot M, Boyer N, et al. Variabilité génétique du virus de l’hépatite C : implications cliniques. Gastroenterol Clin Biol 2000; 24 : 175–84.
  42. Pawlotsky JM, Pellerin M, Bouvier M, et al. Genetic complexity of the hypervariable region 1 (HVR 1) of hepatitis C virus. Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998; 54 : 256–64.
  43. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the non structural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334 : 77–81.
  44. Gervais A, Martinot M, Boyer N, et al. Quantitation of hepatic hepatitis C virus RNA with chronic hepatitis C, relationship with severity of disease, viral genotype and response to treatment. J Hepatol 2001; 35 : 399–405.
  45. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatits C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87 : 331–42.
  46. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4 : 463–7.
  47. Von Weizsacker F, Wieland S, Kock J, et al. Gene therapy for chronic viral hepatitis : ribozymes antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26 : 251–5
  48. Abrignani S, Houghton M, Hsu HH. Perspective for a vaccine against hepatitis C virus. J Hepatol 1999; 31 : 259–263.
  49. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91 : 1294–8.